Important Update for Sage Therapeutics, Inc. Shareholders
The Gross Law Firm has released an important notice aimed at shareholders of Sage Therapeutics, Inc. (SAGE). Investors who purchased shares during the designated class period should pay close attention to this announcement, as this class action may offer a way for those affected to seek recovery.
Eligibility for Lead Plaintiff Appointment
If you bought shares of SAGE during the specified class period, you’re encouraged to reach out to the firm about the option to be appointed as a lead plaintiff. Keep in mind, there’s no obligation to become a lead plaintiff if you wish to participate in any potential recovery.
Details of the Class Period
The class period for this action runs from April 12, 2021, to July 23, 2024. Shareholders who fall within this timeframe may have claims based on misleading statements made by the company.
Allegations Against Sage Therapeutics, Inc.
The lawsuit centers around claims that the company made materially false or misleading statements about its drug Zuranolone, especially regarding its effectiveness in treating Major Depressive Disorder (MDD). There are concerns that the company exaggerated both the drug's potential and its chances of getting regulatory approval from the FDA.
Specific Claims
The primary allegations include:
(i) Zuranolone was thought to be less effective for MDD than advertised, raising doubts about its future approval.
(ii) There are worries about the effectiveness of SAGE-718 for Mild Cognitive Impairment linked to Parkinson's Disease.
(iii) Concerns persist regarding SAGE-324 and its efficacy in treating essential tremors.
Next Steps for Shareholders
For shareholders interested in joining the class action, it is vital to register promptly. The final registration deadline is October 28, 2024. Once registered, shareholders will benefit from a monitoring service that provides updates on the case's progress throughout its duration.
Why Choose the Gross Law Firm?
The Gross Law Firm is a nationally recognized firm that puts a strong emphasis on protecting investor rights. Their commitment is focused on seeking justice for those who have suffered losses due to potential fraud and misleading actions by companies. The firm is dedicated to promoting ethical business practices and accountability.
Contact Information for Inquiries
For more information or any questions, shareholders can get in touch with the Gross Law Firm directly:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: dg@securitiesclasslaw.com
Phone: (646) 453-8903
Frequently Asked Questions
What should I do if I purchased SAGE shares during the class period?
If you bought SAGE shares during the class period, it's advised that you reach out to the Gross Law Firm to explore your options for participating in the class action.
What is the class period for the securities action?
The class period for this action is from April 12, 2021, to July 23, 2024.
What allegations are made against Sage Therapeutics?
The allegations involve false statements regarding the effectiveness of its drugs and their chances of FDA approval.
How can I register for the class action?
Shareholders can register by contacting the Gross Law Firm and providing details about their share purchases.
What benefits do I get from registering?
By registering, you can keep updated on the case and possibly recover any losses you’ve incurred.
